TABLE 5.
Changes on day 1 for CA and AA and the combined groupa
| Function/description | Symbol | Fold change for:
|
P | ||
|---|---|---|---|---|---|
| All | CA | AA | |||
| Antiviral response | |||||
| Interferon-stimulated gene 20 kDa | ISG20 | 2.94 | 2.71 | 3.19 | 0.15 |
| 2′5′-Oligoadenylate synthetase 1, 40/46 kDa | OAS1 | 5.77 | 5.29 | 6.26 | 0.32 |
| 2′5′-Oligoadenylate synthetase 2, 69/71kDa | OAS2 | 4.37 | 4.16 | 4.61 | 0.38 |
| 2′5′-Oligoadenylate synthetase-like | OASL | 6.68 | 6.19 | 7.15 | 0.28 |
| Radical S-adenosyl methionine domain containing 2 | RSAD2 | 15.66 | 14.77 | 16.56 | 0.60 |
| Apoptosis | |||||
| XIAP associated factor-1 | HSXIAPAF1 | 3.40 | 3.17 | 3.61 | 0.50 |
| TRAIL | TNFSF10 | 4.45 | 4.05 | 4.88 | 0.25 |
| Cell proliferation | |||||
| Lysosomal-associated membrane protein 3 | LAMP3 | 9.17 | 8.91 | 9.42 | 0.77 |
| Chemokines | |||||
| Chemokine (C-C motif) ligand 2 | CCL2 | 46.88 | 39.68 | 53.27 | 0.36 |
| Chemokine (C-C motif) receptor 1 | CCR1 | 3.58 | 3.46 | 3.69 | 0.68 |
| Chemokine (C-C motif) ligand 8 | CCL8 | 9.58 | 7.85 | 10.91 | 0.29 |
| Chemokine (C-X-C motif) ligand 11 | CXCL11 | 5.62 | 5.17 | 6.19 | 0.48 |
| Chemokine (C-X-C motif) ligand 10 | CXCL10 | 21.81 | 19.51 | 24.34 | 0.25 |
| Complement pathway | |||||
| Complement component 3a receptor 1 | C3AR1 | 3.02 | 2.80 | 3.31 | 0.21 |
| Serine (or cysteine) proteinase inhibitor | SERPING1 | 10.64 | 9.51 | 11.94 | 0.28 |
| Endonuclease | |||||
| Liver RNase (neurotoxin) | RNAse2 | 2.54 | 2.49 | 2.60 | 0.73 |
| Helicase | |||||
| Hypothetical protein FLJ20035 | FLJ20035 | 3.92 | 4.10 | 3.73 | 0.42 |
| Interferon induced with helicase C domain 1 | IFIH1 | 3.91 | 3.69 | 4.09 | 0.64 |
| Immune response | |||||
| Alpha interferon-inducible protein (clone IFI-15K) | G1P2 | 8.78 | 7.80 | 9.89 | 0.22 |
| Alpha interferon-inducible protein (clone IFI-6-16) | G1P3 | 3.75 | 3.42 | 4.11 | 0.31 |
| Alpha interferon-inducible protein 27 | IFI27 | 25.98 | 21.91 | 29.71 | 0.39 |
| Interferon-induced protein 35 | IFI35 | 3.96 | 3.63 | 4.34 | 0.31 |
| Interferon-induced protein 44 | IFI44 | 5.32 | 5.62 | 5.02 | 0.66 |
| Interferon-induced protein 44 | IFI44L | 7.38 | 7.25 | 7.52 | 0.49 |
| Interferon-induced protein with tetratricopeptide repeats 1 | IFIT1 | 12.68 | 13.10 | 12.30 | 0.88 |
| Interferon-induced protein with tetratricopeptide repeats 3 | IFIT3 | 9.40 | 9.62 | 9.19 | 0.78 |
| Interferon-induced protein with tetratricopeptide repeats 5 | IFIT5 | 2.98 | 2.89 | 3.08 | 0.84 |
| Interferon induced transmembrane protein 1 (9-27) | IFITM1 | 1.82 | 1.77 | 1.86 | 0.55 |
| Interferon induced transmembrane protein 3 (1-8U) | IFITM3 | 2.49 | 2.35 | 2.63 | 0.49 |
| IL-1 receptor antagonist | IL1RN | 4.76 | 4.19 | 5.47 | 0.31 |
| Myxovirus (influenza virus) resistance 1 | MX1 | 5.29 | 5.47 | 5.12 | 0.11 |
| Myxovirus (influenza virus) resistance 2 | MX2 | 3.92 | 3.67 | 4.19 | 0.65 |
| Inflammatory response | |||||
| Heparanase | HPSE | 3.65 | 3.22 | 4.19 | 0.03 |
| Sialoadhesin | SN | 28.31 | 28.66 | 28.02 | 0.96 |
| JAK-STAT cascade | |||||
| N-myc (and STAT) interactor | NMI | 2.60 | 2.47 | 2.76 | 0.35 |
| Signal transducer and activator of transcription 1 (91 kDa) | STAT1 | 2.17 | 2.11 | 2.24 | 0.54 |
| Phospholipid scrambling | |||||
| Phospholipid scramblase 1 | PLSCR1 | 4.00 | 3.75 | 4.29 | 0.31 |
| RNA editing | |||||
| Apolipoprotein B mRNA editing enzyme | APOBEC3A | 4.88 | 4.26 | 5.70 | 0.06 |
| Signal transduction | |||||
| Membrane-spanning 4 domains, subfamily A, member 4 | MS4A4A | 5.51 | 4.68 | 6.40 | 0.07 |
| All | CA | AA | |||
| Toll pathway | |||||
| Toll-like receptor 7 | TLR7 | 5.66 | 5.37 | 5.98 | 0.51 |
| Transcription factor/repressor | |||||
| CD38 antigen (p45) | CD38 | 2.46 | 2.29 | 2.64 | 0.16 |
| Homeobox (expressed in embryonic stem cells) 1 | HESX1 | 22.41 | 19.63 | 25.53 | 0.24 |
| Gamma interferon-inducible protein 16 | IFI16 | 2.07 | 2.04 | 2.10 | 0.67 |
| Interferon regulatory factor 7 | IRF7 | 3.84 | 3.49 | 4.22 | 0.13 |
| Lectin, galactoside-binding, soluble, 9 (galectin 9) | LGALS9 | 2.56 | 2.49 | 2.63 | 0.74 |
| Lymphocyte antigen 6 complex, locus E | LY6E | 3.95 | 3.79 | 4.13 | 0.73 |
| Nuclear antigen Sp100 | SP100 | 1.92 | 1.96 | 1.88 | 0.69 |
| SP110 nuclear body protein | SP110 | 1.71 | 1.75 | 1.67 | 0.65 |
| T-box 3 (ulnar mammary syndrome) | TBX3 | 5.93 | 5.90 | 5.96 | 0.94 |
| Ubiquitin pathway | |||||
| Hect domain and RLD 5 | HERC5 | 7.30 | 7.13 | 7.47 | 0.75 |
| Hect domain and RLD 6 | HERC6 | 5.01 | 4.82 | 5.24 | 0.43 |
| Promyelocytic leukemia | PML | 3.31 | 3.18 | 3.44 | 0.48 |
| Ubiquitin-conjugating enzyme E2L 6 | UBE2L6 | 2.69 | 2.51 | 2.90 | 0.07 |
| Ubiquitin-specific protease 18 | USP18 | 9.62 | 8.37 | 11.10 | 0.12 |
| Unknown function | |||||
| 28-kDa interferon-responsive protein | IFRG28 | 4.31 | 3.69 | 5.01 | 0.01 |
a
Changes (n-fold) were defined as +averageday 1/averageday 0, if averageday 1 > averageday 0, or as −averageday 0/averageday 1, if averageday 1 < averageday 0. The standard error of a change (n = fold) was estimated by the delta method. A two-sample Z test was constructed to compare changes (n = fold) between CA and AA according to the equation Z = FCCA − FCAA/(std.FCCA2 + std.FCAA2)1/2, where Z is approximately standard normal, FCCA and FCAA are the changes (n-fold) for CA and AA, respectively, and std.FCCA and std.FCAA are corresponding standard errors.